In 2015, NICE said that BioMarin's Vimizim could be used to treat patients with the ultra-rare disease Morquio A syndrome, while real-world data was collected on its efficacy. Now – almost seven ...
In the largest study of its kind globally, UK clinicians and researchers at Royal Manchester Children’s Hospital (RMCH) part of Manchester University NHS Foundation Trust (MFT), and Great Ormond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback